Human Recombinant Hyaluronidase Injections For Upper Limb Muscle Stiffness in Individuals With Cerebral Injury: A Case Series.

摘要: Abstract Spasticity, muscle stiffness and contracture cause severe disability after central nervous system injury. However, current treatment options for spasticity produce weakness which can impede movement, do not directly address stiffness. Here we propose that the accumulation of hyaluronan within muscles promotes development stiffness, report with enzyme hyaluronidase increases upper limb movement reduces without producing weakness. 20 patients unilateral received multiple intramuscular injections human recombinant saline at a single visit. The safety efficacy injections, passive active eight joints were assessed four time points: pre-injection (T0), 2weeks (T1), 4–6weeks (T2), 3–5months post-injection (T3). There no clinically significant adverse effects from injections. Passive all joints, most increased T1, persisted T2 T3 joints. modified Ashworth scores also declined significantly over post-injection. Hyaluronidase offer safe potentially efficacious in neurologically impaired individuals. These results warrant confirmation placebo-controlled clinical trials.